Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differences between normal and CML stem cells: potential targets for clinical exploitation.

A C Eaves1, M J Barnett, L Ponchio

  • 1Terry Fox Laboratory and Division of Hematology, British Columbia Cancer Agency and University of British Columbia, Vancouver, Canada.

Stem Cells (Dayton, Ohio)
|September 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polycomb contraction differentially regulates terminal human hematopoietic differentiation programs.

BMC biology·2022
Same author

Regulation of p21 by TWIST2 contributes to its tumor-suppressor function in human acute myeloid leukemia.

Oncogene·2014
Same author

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Ex vivo expansion of normal and chronic myeloid leukemic stem cells without functional alteration using a NUP98HOXA10homeodomain fusion gene.

Leukemia·2012
Same author

Insights into the stem cells of chronic myeloid leukemia.

Leukemia·2010
Same author

Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.

Leukemia·2010
Same journal

Brent A. Reynolds, pioneer of adult neural stem cell biology.

Stem cells (Dayton, Ohio)·2026
Same journal

CircVapa promotes the abnormal differentiation of small intestinal epithelial stem cells in diabetic state.

Stem cells (Dayton, Ohio)·2026
Same journal

Transforming Growth Factor beta-2 (TGFβ2) Drives Trabecular Meshwork Progenitor Cell Differentiation Through SMAD2/3 Signalling.

Stem cells (Dayton, Ohio)·2026
Same journal

Circular RNA circEGFR overexpression attenuates chemosensitivity and enhances cancer stemness via targeting IGF2BP2/SOX2 in breast cancer cells.

Stem cells (Dayton, Ohio)·2026
Same journal

Regeneration of the mammalian brain: a relic of evolution?

Stem cells (Dayton, Ohio)·2026
Same journal

Mitochondrial transfer technologies with molecular insights into clinical applications.

Stem cells (Dayton, Ohio)·2026
See all related articles

Chronic myeloid leukemia (CML) involves abnormal proliferation of CML progenitors. Researchers are exploring in vitro purging strategies to reduce leukemic stem cells in CML marrow autografts, showing promising early results.

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Chronic myeloid leukemia (CML) is characterized by excessive CML progenitor amplification.
  • Leukemic progenitors exhibit increased proliferation and anomalous cycling behavior.
  • CML progenitors show a reduced ability to be inhibited by certain chemokines.

Purpose of the Study:

  • To investigate the dysregulation of CML progenitor cells.
  • To evaluate the potential of in vitro purging strategies for CML stem cells.
  • To assess the feasibility of reducing leukemic stem cell content in CML marrow autografts.

Main Methods:

  • Quantification of colony-forming cells (CFC) using standard in vitro assays.
  • Detection of long-term culture-initiating cells (LTC-IC) to assess primitive progenitor populations.

Related Experiment Videos

  • In vitro incubation of CML cells to observe differentiation probability and LTC-IC activity.
  • Clinical trials of an in vitro purging strategy for CML marrow autografts.

    • Main Results:

    • CML progenitors demonstrate increased proliferative activity and anomalous in vivo cycling.
    • A selective inability of CML progenitors to be inhibited by specific chemokines was observed.
    • CML stem cells exhibit an upregulated differentiation probability, leading to loss of LTC-IC activity in vitro.
    • Initial clinical studies show the feasibility of an in vitro purging strategy, with encouraging results from a larger trial.

    Conclusions:

    • Differential behavior of normal and CML cells in vitro can be exploited for purging leukemic stem cells.
    • In vitro purging strategies show promise for reducing leukemic stem cell burden in CML marrow autografts.
    • Preclinical models using immunodeficient mice may aid in evaluating novel CML eradication treatments.